MGMT and Miyoshi myopathy: Since the ERK inhibitor vMF was approved by the FDA in 2011 and has since been widely applied in the clinical management of MM, this oral targeted drug is rarely discontinued due to adverse reactions, which helps to elucidate the mechanism of MGMT inhibitors used as TMZ sensitisation agents.